Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018

Sep 10, 2018

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

September 10, 2018

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Glenmark secures marketing authorization in Germany for its generic version of Seretide® Accuhaler®

With reference to the subject mentioned above, kindly find attached media release which is selfexplanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited

Digitally signed by HARISH HARISH VINAYAK KUBER VINAYAK KUBER Date: 2018.09.10 08:39:38 +05'30'

Harish Kuber Company Secretary & Compliance Officer

Encl: as above

==> picture [596 x 84] intentionally omitted <==

Press Release

For Immediate Release

Glenmark secures marketing authorization in Germany for its generic version of Seretide® Accuhaler®

• This approval affirms Glenmark’s capabilities in the complex inhaled respiratory products segment

• Glenmark has already launched its generic version of Seretide Accuhaler in Denmark, Sweden and Norway

Mumbai, India, September 10, 2018: Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced today that its subsidiary Glenmark Arzneimittel GmbH has secured marketing authorization in Germany for Fluticasone/Salmeterol dry powder inhaler (DPI), a generic version of GlaxoSmithKline’s Seretide® Accuhaler®.

Fluticasone/Salmeterol DPI is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark will sell the product in Germany under the name “SALFLUTIN”.

“This approval validates Glenmark’s capabilities in the complex inhaled respiratory products segment. Upon launch, generic Fluticasone/Salmeterol DPI will be Glenmark’s first inhalation product available in Germany. There is huge potential for the product in Germany and we are optimistic that it will help enhance growth of the European business,” said Achin Gupta, Executive Vice President & Business Head of Europe and Latin America, Glenmark Pharmaceuticals.

Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. (Celon) in 2015 to develop and market generic Fluticasone/Salmeterol DPI in 15 European countries.

The company has already launched this product in Denmark, Sweden and Norway.

According to IQVIA data, Fluticasone/Salmeterol dry powder inhaler (DPI) had sales of USD 844 million in Europe in the 12 month period ended March 2018.

--End--

==> picture [596 x 29] intentionally omitted <==

1

==> picture [596 x 84] intentionally omitted <==

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Isha Trivedi Glenmark, Mumbai, India Tel: +91 22 4018 9801 Email: corpcomm@glenmarkpharma.com

==> picture [596 x 29] intentionally omitted <==

2